Compares tumor-localizing effects of Lipoxin A4 and Nanolipoxin A4 in osteosarcoma, indicating potential for targeted therapy.
-based strategies in osteosarcoma and demonstrate that nanoformulation provides tumor-localizing behavior while maintaining an acceptable short-term tolerability profile in this PDX setting.
No takes yet. Share an insight, caveat, or question.
Gomes-da-Silva et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: